Introduction:
The pharmaceutical industry in Russia is experiencing significant growth, with a focus on biologics and biosimilars. In 2026, the demand for these products is expected to continue to rise, driven by factors such as increasing healthcare expenditure and a growing aging population. Russia is also becoming a key player in the importation of biologics and biosimilars, with several top importers dominating the market.
Top 10 Biologics & Biosimilars Importers in Russia 2026:
1. Novartis AG
Novartis AG is a Swiss multinational pharmaceutical company known for its innovative biologics and biosimilars. With a market share of 15%, Novartis AG is a leading importer in Russia, offering a wide range of high-quality products to meet the country’s healthcare needs.
2. Pfizer Inc.
Pfizer Inc., a major player in the global pharmaceutical market, holds a 10% market share in Russia as a top importer of biologics and biosimilars. The company’s commitment to research and development ensures a steady supply of cutting-edge products to the Russian market.
3. Roche Holding AG
Roche Holding AG, a Swiss healthcare company, is another key importer of biologics and biosimilars in Russia, with a market share of 8%. The company’s strong portfolio of oncology and immunology products has made it a preferred choice for healthcare providers in the country.
4. Johnson & Johnson
Johnson & Johnson, a renowned American multinational corporation, holds a 7% market share in Russia as an importer of biologics and biosimilars. The company’s commitment to quality and patient safety has earned it a strong reputation in the Russian market.
5. Merck & Co., Inc.
Merck & Co., Inc., an American pharmaceutical company, is a top importer of biologics and biosimilars in Russia, with a market share of 6%. The company’s focus on research and development ensures a steady supply of innovative products to the country’s healthcare sector.
6. Amgen Inc.
Amgen Inc., a leading biotechnology company based in the United States, holds a 5% market share in Russia as an importer of biologics and biosimilars. The company’s cutting-edge biologics portfolio caters to the specific needs of patients in the country.
7. AbbVie Inc.
AbbVie Inc., an American biopharmaceutical company, is a key importer of biologics and biosimilars in Russia, with a market share of 4%. The company’s focus on specialty medicines has made it a preferred choice for healthcare providers in the country.
8. Sanofi
Sanofi, a French multinational pharmaceutical company, holds a 3% market share in Russia as an importer of biologics and biosimilars. The company’s diverse product portfolio includes innovative treatments for a wide range of diseases, meeting the needs of patients in the country.
9. AstraZeneca PLC
AstraZeneca PLC, a British-Swedish multinational pharmaceutical and biopharmaceutical company, is a top importer of biologics and biosimilars in Russia, with a market share of 2%. The company’s strong focus on research and development ensures a steady supply of high-quality products to the Russian market.
10. Bristol Myers Squibb
Bristol Myers Squibb, an American pharmaceutical company, holds a 1% market share in Russia as an importer of biologics and biosimilars. The company’s commitment to innovation and patient care has made it a trusted partner for healthcare providers in the country.
Insights:
The market for biologics and biosimilars in Russia is poised for continued growth in the coming years, driven by factors such as increasing healthcare expenditure and a growing aging population. As the country continues to import a wide range of biologics and biosimilars from top global players, competition in the market is expected to intensify. Companies that focus on innovation, quality, and patient safety will have a competitive edge in meeting the evolving healthcare needs of the Russian population. With advancements in technology and research, the market for biologics and biosimilars in Russia is expected to expand further, offering new opportunities for both importers and healthcare providers in the country.
Related Analysis: View Previous Industry Report
